KRCC1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, featuring a disrupted KRCC1 gene. This loss-of-function model is generated by transient expression of Cas9 and a KRCC1-targeting guide RNA, resulting in a mixed population of gene-edited cells without clonal selection. The polyclonal format maintains cellular heterogeneity, mimicking native tissue diversity and minimizing clonal artifacts in functional assays.
The HeLa parental cell line is a human cervical adenocarcinoma epithelial line, immortalized and characterized by HPV18 integration. Its defective p53 and Rb pathways, coupled with a transformed phenotype, provide a genetically tractable background for studying oncogenic processes and DNA damage response. HeLa’s robust growth and ease of manipulation make it a workhorse for cell biology research.
KRCC1 functions as a substrate-specific adaptor for the RNF14 E3 ubiquitin ligase complex. It interacts with RNF14, E2 ubiquitin-conjugating enzymes, and proteasome components to facilitate ubiquitination and subsequent degradation of target proteins. This activity is engaged downstream of DNA damage signals and cell cycle kinases, modulating the turnover of DNA repair factors and cell cycle regulators. KRCC1 thereby influences the DNA damage response and cell cycle checkpoints, with representative pathway components including RNF14, ubiquitin, the proteasome, and DNA repair proteins.
In the HPV-positive HeLa context, KRCC1 depletion can exacerbate genomic instability and dysregulate proteostasis. Given its described roles in renal cell carcinoma and glioblastoma, these knockout cells enable dissection of KRCC1-dependent pathways in cervical cancer and comparative oncology. The model is valuable for evaluating synthetic lethality and drug sensitivities under conditions of compromised DNA repair and proteolytic control.
Applications include Western blotting and RT-qPCR to confirm KRCC1 loss and quantify downstream effectors, co-immunoprecipitation with RNF14 to assess complex formation, and immunofluorescence for subcellular localization. Functional studies encompass flow cytometry for cell cycle and apoptosis, DNA damage assays (??H2AX foci), and proteasome inhibition treatments. These assays support drug screening and mechanistic investigations of ubiquitin-mediated signaling. Contact Ascent Research for further information.
